Lead Product(s) : Tovorafenib,Pimasertib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DAY101 (Tovorafenib) is an investigational, oral, brain-penetrant, highly-selective type II pan-RAF kinase inhibitor designed to target a key enzyme in the MAPK signaling pathway, which is being investigated in primary brain tumors or brain metastases of...
Product Name : Ojemda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Tovorafenib,Pimasertib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tovorafenib,Pimasertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors
Details : DAY101 has demonstrated encouraging anti-tumor activity as a monotherapy in patient populations where MAPK pathway alterations are believed to play an important role in driving disease progression.
Product Name : Ojemda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : Tovorafenib,Pimasertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pimasertib,Tovorafenib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Day One Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Day One Expands Clinical-Stage Oncology Pipeline; Announces Global License Agreement with Merck KGaA
Details : Exclusive license agreement broadens Day One’s clinical-stage pipeline of targeted cancer therapies with the additions of pimasertib and MSC2015103B. Day One plans to study the combination of pimasertib and DAY101 in patients ≥12 years of age with ad...
Product Name : MSC19363639B
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : Pimasertib,Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Day One Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement